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Summary
 
Systemic lupus erythematosus (SLE) is a potentially fatal non–organ-specific autoimmune dis-
ease that predominantly affects women. Features of the disease include inflammatory skin le-
sions and widespread organ damage caused by deposition of anti-dsDNA autoantibodies. The
mechanism and site of production of these autoantibodies is unknown, but there is evidence
that interferon (IFN) 
 
g
 
 plays a key role. We have used the involucrin promoter to overexpress
IFN-
 
g
 
 in the suprabasal layers of transgenic mouse epidermis. There was no evidence of organ-
specific autoimmunity, but transgenic animals produced autoantibodies against dsDNA and his-
tones. Autoantibody levels in female mice were significantly higher than in male transgenic
mice. Furthermore, there was IgG deposition in the glomeruli of all female mice and histolog-
ical evidence of severe proliferative glomerulonephritis in a proportion of these animals. Our
findings are consistent with a central role for the skin immune system, acting under the influ-
ence of IFN-
 
g
 
, in the pathogenesis of SLE.
 
S
 
ystemic lupus erythematosus (SLE) is a relatively com-
mon non–organ-specific autoimmune disease, with a
prevalence comparable to that of multiple sclerosis (1). SLE
predominantly affects women, the female/male ratio being
 
z
 
9:1 (2). In this condition, splenomegaly and inflamma-
tory skin lesions of varying severity occur in association
with autoantibody production against a variety of nuclear
antigens and multiple organ damage (1). Renal involve-
ment complicates 60–70% of cases and its severity largely
determines prognosis (3). The renal glomeruli are the prime
site of injury due to the presence of anti-dsDNA autoanti-
bodies in the mesangium and capillary walls (4). Anti-dsDNA
antibodies intravenously administered to mice have been
shown to induce glomerulonephritis (GN)
 
1
 
, although the
reason for tissue injury remains controversial (1, 4).
The mechanism of antinuclear autoantibody production
is unknown, but there is evidence that IFN-
 
g
 
 plays a role.
First, the emergence of SLE, with de novo anti-dsDNA
antibody production, has been described in patients receiv-
ing systemic treatment with IFN-
 
a
 
 or -
 
g
 
 (5, 6). Second,
manipulation of the circulating amount and function of
IFN-
 
g
 
 can profoundly alter the course of lupus in mouse
models of the disease; systemic administration of IFN-
 
g
 
 ac-
celerates the rate of progression to GN in lupus prone
(NZB 
 
3
 
 NZW)F1 mice (7) and administration of anti–
IFN-
 
g
 
 or soluble IFN-
 
g
 
 receptor to these animals can de-
lay development of the disease (7, 8). Nevertheless, the
precise effects of IFN-
 
g
 
 on murine lupus appear to be crit-
ically dependent on the dosage of the cytokine, the timing
of administration, and the genetic background of the ani-
mal. For example, systemic administration of IFN-
 
g
 
 to lu-
pus prone MRL/lpr-lpr mice has no effect on the course of
the disease (9).
The site of production of pathogenic antinuclear autoan-
tibodies in SLE is obscure. However, the observation that
UV radiation, a factor known to exacerbate the disease, can
induce translocation of nuclear antigens to the keratinocyte
surface suggests that the skin immune system may be in-
volved (10, 11). We have recently made transgenic mice in
which IFN-
 
g
 
 is expressed in the suprabasal layers of the
epidermis under the control of the involucrin promoter (12).
This results in marked overexpression of IFN-
 
g
 
 in the epi-
dermis but no increase in the level of IFN-
 
g
 
 in the blood.
IFN-
 
g
 
 transgenic mice develop a nonblistering inflamma-
tory skin disease with dermal edema and have marked sple-
nomegaly. In addition, serum from the transgenic mice
contains antibodies that produce a nuclear pattern of stain-
ing on sections of normal mouse epidermis (12). In view of
these findings, we investigated IFN-
 
g
 
 transgenic mice for
the presence of murine lupus.
 
1
 
Abbreviations used in this paper:
 
 ENA, extractable nuclear antigens; GN,
glomerulonephritis; HRP, horseradish peroxidase.
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Materials and Methods
 
Preparation of Transgenic Mice.
 
This was carried out as previ-
ously described (12). In brief, a transgene with the cDNA for
murine IFN-
 
g
 
 under the control of the involucrin promoter was
injected into fertilized oocytes from (CBA 
 
3
 
 C57/BL10)F1 mice.
Three independent founder lines were generated: line 1205D
contains 2 copies of the transgene, 1205C contains 6 copies, and
1212F contains 32 copies. The characteristics of the mice which
were previously reported (12) and are reported here were ob-
served in all three founder lines.
 
IFN-
 
g
 
 ELISA.
 
Serum from 15 transgenic mice (8 males, 7
females) aged 4–13 mo was tested for the presence of IFN-
 
g
 
 us-
ing a murine IFN-
 
g
 
 Cytoscreen immunoassay kit (Biosource
Intl., Camarillo, CA; reference 12). Recombinant mouse IFN-
 
g
 
(Genzyme, Cambridge, MA) in the range of 10–500 pg/ml was
used to standardize for known amounts of protein. In addition,
extracts of renal tissue from two 7-mo-old transgenic female mice
and two age- and sex-matched negative littermate controls were
prepared by sonication on ice in 1 ml PBS containing 0.2 mM
PMSF and 1 
 
m
 
M pepstatin. IFN-
 
g
 
 levels in both kidneys from
each animal were measured using the IFN-
 
g
 
 Cytoscreen immu-
noassay kit and expressed per microgram of total protein present.
Experiments were performed in triplicate and chromogenic re-
sults were read on a spectrophotometer at OD
 
450
 
.
 
Indirect Immunofluorescence on Normal Mouse Skin and Esopha-
gus.
 
Serum samples from transgenic mice and negative control
littermates were screened for the presence of autoantibodies by in-
direct immunofluorescence on normal mouse tail skin or esopha-
gus. Unfixed, 8-
 
m
 
m-thick frozen sections of normal mouse skin/
esophagus were allowed to air-dry at room temperature for 30
min before staining. Sections were blocked for 30 min in PBS
containing 1 mM CaCl
 
2
 
, 1 mM MgCl
 
2
 
 (PBSABC), and 10% FCS
(Imperial Laboratories, Andover, UK) followed by incubation
with mouse serum at a dilution of 1:10 in PBSABC for 45 min.
Sections were then incubated for 45 min with Texas red–conju-
gated goat anti–mouse IgG (Jackson ImmunoResearch Labs, Inc.,
West Grove, PA) at a dilution of 1:100 in PBSABC.
 
Cell Culture.
 
Isolation of human keratinocytes from newborn
foreskin and cultivation on a feeder layer of mitomycin C–treated
3T3 cells have been previously described (13, 14). The culture me-
dium consisted of one part Ham’s F12 medium and three parts
DMEM, supplemented with 1.8 
 
3
 
 10
 
2
 
4
 
 M adenine, 10% FCS,
0.5 
 
m
 
g/ml hydrocortisone, 5 
 
m
 
g/ml insulin, 10
 
2
 
10
 
 M cholera
toxin, and 10 ng/ml epidermal growth factor. An established mouse
keratinocyte line, provided by Dr. Rosario Romero (Imperial Can-
cer Research Fund) was grown under the same conditions as for
human keratinocytes, except that the incubation temperature was
32 rather than 37
 
8
 
C.
 
Immunofluorescence Staining of Cultured Keratinocytes.
 
Mouse and
human keratinocytes grown on coverslips were fixed and perme-
abilized for 10 min using a 50:50 methanol/acetone solution at
 
2
 
20
 
8
 
C or in 3.7% formaldehyde for 10 min at room tempera-
ture, followed by 0.1% Triton X-100 in PBS for 5 min at room
temperature. The same staining patterns were observed with each
fixation technique. The coverslips were incubated with transgenic
mouse serum diluted 1:10 in PBSABC for 45 min. After washing
in PBS, coverslips were incubated with Texas red–conjugated
goat anti–mouse IgG for 45 min. In some experiments, coverslips
were incubated with rabbit antidesmoglein antibody 919 (recog-
nizing the cytoplasmic repeat region of desmoglein-1 and -2,
provided by Dr. Anthony Magee, National Institute for Medical
Research, London, UK; reference 15), followed by Texas red–
conjugated donkey anti–rabbit IgG (Jackson ImmunoResearch
Labs.). All incubations and PBS washes were carried out at room
temperature. Stained cells were mounted in Gelvatol and exam-
ined using an Axiophot microscope (Carl Zeiss, Inc., Thorn-
wood, NY).
 
Western Blotting.
 
Confluent cultured mouse and human kera-
tinocytes were lysed on ice in extraction buffer containing 150
mM NaCl, 50 mM Tris-HCl (pH 7.4), 5 mM EDTA, 0.1% Tri-
ton X-100, 2 mM PMSF, and 0.01% leupeptin. The lysates were
centrifuged at 14,000 rpm for 5 min and the pellets were dis-
carded. The supernatants were subjected to SDS-PAGE on 6 or
8% slab gels, followed by transblotting to nitrocellulose paper.
Transblotting was carried out in 48 mM Tris, 387 mM glycine,
and 3.5 mM SDS containing 20% methanol for 2 h at 35 V fol-
lowed by 2 h at 70 V. The blots were blocked overnight in 5%
skim milk in PBS containing 0.01% Tween (PBS/T), then incu-
bated for 1 h with serum from transgenic or control mice diluted
at 1:200 in PBS/T containing 0.1% BSA (Sigma Chemical Co.,
Poole, Dorset, UK). Nitrocellulose strips were then incubated for
1 h with horseradish peroxidase (HRP)–conjugated rabbit anti–
mouse Ig (DAKO, High Wycombe, UK) diluted 1:5,000 in PBS/T
containing 0.1% BSA. Between antibody incubations, strips were
washed three times with PBS/T. Additional strips were incubated
with rabbit antidesmoglein antibody 145 (raised against the repeat
region of desmoglein-1 and recognizing all three desmogleins, pro-
vided by Dr. Anthony Magee) followed by HRP-conjugated
donkey anti–rabbit Ig (Amersham International, Little Chalfont,
UK). All incubation and washing steps were performed at room
temperature. The peroxidase activity was visualized by enhanced
chemiluminescence (ECL; Amersham International).
 
Assay for Extractable Nuclear Antigens (ENA).
 
Serum samples
were screened for the presence of antibodies against extractable
nuclear antigens (Sm, U1RNP, SS-A [Ro], SS-B [La], Jo1, and
Scl-70) using a commercially available ENA screening counter
current immunoelectrophoresis (CIE) kit (The Binding Site, Ltd.,
Birmingham, UK). Transgenic serum found to be positive on this
screen was further characterized using an ENA typing CIE kit
specific for the same antigens (The Binding Site, Ltd.). For ENA
screening, 120 
 
m
 
l of ENA extract (buffered sheep spleen extract
preserved in 100 mM PMSF and 10 mM mercaptoethanol) and
20 
 
m
 
l of test serum were applied to the surface of an agarose gel
by means of an application mask. For ENA typing, 15–20 
 
m
 
l of
test serum and 55–100 
 
m
 
l individual ENAs were impaired. For
both procedures electrophoresis was carried out at 50 V for 75
min on a Beckman Paragon power pack. Gels were stained in
Acid blue 29 in 5% vol/vol acetic acid for 2 s and destained in 5%
vol/vol acetic acid for 5 min. Gels were dried completely by
placing in a 45
 
8
 
C incudryer for 15 min and were then examined
for a visible immunoprecipitate.
 
Crithidia luciliae Staining.
 
Serum samples from transgenic and
negative control littermates were screened for the presence of
anti-dsDNA antibodies using a commercially available 
 
C. luciliae
 
dsDNA kit (The Binding Site, Ltd.). In brief, slides coated with
 
C. luciliae
 
 were incubated for 30 min at room temperature with
serum samples diluted 1:10 in PBS. The slides were washed in
PBS and then incubated for 30 min with FITC-conjugated goat
anti–mouse IgG (Jackson ImmunoResearch Labs.). After further
washing, the slides were mounted in Gelvatol (Monsanto Chem-
ical Co., St. Louis, MO) and viewed using a confocal micro-
scope.
 
Antihistone and Anti-dsDNA ELISA.
 
The levels of antihis- 
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tone and anti-dsDNA antibodies in serum were measured using a
modification of previously described methods (16). Calf thymus
histones (Sigma Chemical Co.) were diluted in PBS to a concen-
tration of 2.5 
 
m
 
g/ml and 0.2 ml of this antigen solution was
added to each well of an Immulon II microtiter plate (Dynatech
Labs., Inc., Chantilly, VA). After overnight incubation at 4
 
8
 
C, wells
were coated with 0.4 ml gelatin (1 mg/ml in PBS) for at least 24 h
at 4
 
8
 
C. After washing, 0.2 ml of serum samples diluted 1:1,000–
1:4,000 in 0.1% Tween, 1 mg/ml gelatin, and 0.5% BSA in PBS
were added and incubated for 1.5 h at room temperature. After
washing, HRP-conjugated rabbit anti–mouse Ig (DAKO) diluted
1:4,000 in 0.1% Tween in PBS was added. After 1.5 h of incuba-
tion at room temperature, the wells were washed and substrate
solution was added. The OD was then read with an automated
spectrophotometer at 492 nm.
To measure anti-dsDNA antibody levels, wells were coated with
dsDNA (Sigma Chemical Co.). To attach dsDNA, microtiter
wells were first coated with poly-
 
l
 
-lysine (Sigma Chemical Co.)
at 5.0 
 
m
 
g/ml in H
 
2
 
O for 1.5 h at 37
 
8
 
C. After washing, dsDNA
was added at 5.0 
 
m
 
g/ml in PBS and incubated overnight at 4
 
8
 
C.
After washing, serum samples diluted 1:250–1:4,000 were added
as described above.
All ELISA tests were run in triplicate. In addition, serum sam-
ples were checked for nonspecific binding to control wells lacking
antigen. Plates were assessed for contamination with ssDNA using
a serum sample known to be strongly positive for anti-ssDNA an-
tibodies and negative for anti-dsDNA antibodies (provided by
Tim Plant, Regional Immunology Department, Birmingham Heart-
lands Hospital, Birmingham, UK). Sera from four female MRL/
lpr mice (
 
z
 
6-mo-old), known to be strongly positive for antinu-
clear antibodies, were used as positive controls in antihistone and
anti-dsDNA ELISAs (provided by Dr. C.T. Ravirajan, Blooms-
bury Rheumatology Unit, University College, London, UK). In
both the antihistone and the anti-dsDNA ELISAs, autoantibody
levels in transgenic mice were compared to those in littermate
controls. ODs obtained with serum from different groups of ani-
mals were compared using the Mann-Whitney 
 
U
 
 test.
 
Immunofluorescence Detection of Kidney Deposits.
 
Kidney tissue
from transgenic mice and negative control littermates was snap-
frozen in an isopentane bath cooled in liquid nitrogen. Frozen
sections embedded in OCT (Tissue Tek
 
TM
 
; Miles Inc., Elkhart,
IN) were cut at 5–8 
 
m
 
m thickness. Sections were air dried and
blocked for 30 min with goat serum. Sections were then incu-
bated for 45 min with Texas red–conjugated goat anti–mouse
IgG diluted at 1:100. Each antibody incubation was carried out at
room temperature and was followed by thorough washing in
PBS. Stained sections were mounted in Gelvatol and examined
using a Zeiss Axiophot microscope.
 
Histology and Electron Microscopy.
 
For light microscopy, kid-
ney tissue was fixed in formalin, paraffin-embedded, and sections
were stained with hematoxylin and eosin, or periodic acid Schiff.
For electron microscopy, kidney tissue was fixed in 4% buffered
glutaraldehyde at 4
 
8
 
C, post-fixed in osmium tetroxide, and ultra
thin sections were stained with uranyl acetate and Reynold’s lead
citrate.
 
Results
 
Animals Studied.
 
34 transgenic animals and 12 litter-
mate controls were examined. Tables 1 and 2 list the age
and sex of each animal and summarize several of the pa-
 
Table 1.
 
Transgenic Mice Examined
 
Animal Sex Age
Serum
IFN-
 
g
 
IIF
Staining
pattern
on CK
Western
blot CL ENA
Kidney
DIF
 
pg/ml
 
1M 9 N
 
21 2 1
 
2M 5
 
12 1 2
 
3M 1 2 U N
 
11
 
4M 4 1 5
5M 4 U N
6M 5 4 0
 
1
 
N
 
21 2 2
 
7M 1 2
 
11 1
 
8M 9 U N
 
1 2 1 111
 
9M 9
 
1
 
N
 
21 2 2
 
10 F 12 UN
 
1
 
11 F 7 UN
 
1
 
N
 
21 1 1
 
12 F 6 N
 
21 2 1
 
13 F 10
 
11 1
 
14 F 10 UN
 
1 1 111
 
15 F 11 UN
 
1
 
16 F 4 UN N
 
21
 
Sm
 
111
 
17 4
 
1
 
N
 
21 2 2
 
18 M 12 15 2
19 M 5 30 1 N 2 1 2 111
20 M 5 1 N 22 2 2
21 M 8 1
22 M 8 1 N 2 111
23 M 8 1
24 M 9 1
25 M 5 2
26 M 4 2
27 M 13 2
28 F 3 2
29 M 13 UN
30 F 12 UN
31 F 12 UN
32 F 12
33 F 7 1
34 F 7 1
Age is quoted in months. M, male; F, female; IIF, indirect immunoflu-
orescence on normal mouse skin or esophagus; CK, cultured kerati-
nocytes; CL, testing for anti-dsDNA on C. luciliae; ENA, antibodies
against extractable nuclear antigens; DIF, direct immunofluorescence;
UN, undetectable; N, nuclear staining on cultured mouse and/or hu-
man keratinocytes. On direct immunofluorescence of kidneys, glomer-
ular staining intensity ranged from none (2) to mild/focal (1), moder-
ate (11), or intense (111). The presence of subendothelial-mesangial
deposits was confirmed by electron microscopy in mice 13 and 16.
There was histological evidence of severe proliferative GN in animals
12, 14, and 16 (see Table 3).1454 Lupus Nephritis in IFN-g Transgenic Mice
rameters measured. The majority of animals previously an-
alyzed were under 5 mo of age (12). However, the mean
age of the transgenic mice and negative control littermates
in this study was greater; 8.1 and 9.6 mo, respectively. None
of the transgenic mice in the early study had detectable lev-
els of circulating IFN-g (12). We used the same ELISA
method to test the serum of 15 of the present group of
transgenic mice and 5 negative littermate controls (see Ta-
bles 1 and 2). All 5 controls and 11 of the transgenic ani-
mals had no detectable serum IFN-g, but 4 male transgenic
mice had small amounts (15–40 pg/ml; limit of detection
in the assay is 5 pg/ml). We had previously reported that
IFN-g was readily detectable in skin of transgenic but not
control mice, the 1212F line having the highest concentra-
tion (33 pg/cm2; reference 12). We measured IFN-g levels
in kidney tissue extracts of two transgenic females from this
founder line (Nos. 33 and 34, Table 1) and two littermate
controls (C11 and C12, Table 2). The level of IFN-g de-
tected was 4 pg/mg total protein in the transgenic mice and
6 pg/mg in the controls.
IFN-g Transgenic Mice Produce Non–organ-specific Antinu-
clear Autoantibodies. Previous studies in transgenic models
have shown that local overproduction of IFN-g can result
in tissue-specific autoimmunity (17, 18). To test whether the
autoantibodies in our transgenic mice were keratinocyte-
specific we stained sections of mouse esophagus and skin in
which keratinocytes, stromal fibroblasts, muscle cells, and
endothelial cells could all be identified. Positive staining of
all cell types was observed (Table 1 and data not shown).
Serum from 14 out of 17 transgenic mice was positive. Se-
rum from 6 out of 7 littermate controls was negative.
Table 2. Negative Control Littermates of Transgenic Mice 
Examined
Animal Sex Age
Serum
IFN-g IIF CL
Kidney
DIF
pg/ml
C1 M 12 22 2
C2 F 10 22 2
C3 F 3 22
C4 F 10 22 2
C5 M 13 UN 22 2
C6 M 13 UN 22 2
C7 M 13 12
C8 F 12 UN 2
C9 F 11 UN 2
C10 M 4 UN 2
C11 F 7 2
C12 F 7 2
Age is quoted in months. M, male; F, female; IIF, indirect immuno-
fluorescence on normal mouse skin/esophagus; DIF, direct immunoflu-
orescence; CL, testing for anti-dsDNA on C. luciliae; UN, undetectable.
Absence of glomerular Ig deposits was confirmed by electron micros-
copy in mice C4 and C5.
Figure 1. Indirect immunofluorescence staining of cultured (A and B)
mouse and (C) human keratinocytes. (A and C) Stained with serum from
a transgenic mouse (diluted 1:10). (B) Stained with antidesmoglein anti-
body. Scale bar (A and B): 30 mm; (C): 60 mm.1455 Seery et al.
Autoantibodies directed against membrane antigens are a
feature of several autoimmune skin diseases, the antigens
frequently being proteins involved in cell–cell or cell–extracel-
lular matrix adhesion (19, 20). The cellular distribution of
the antigens recognized by antibodies in the serum of the
IFN-g transgenic mice was examined by staining cultured
mouse and human keratinocytes (Fig. 1, A and C). In the
10 serum samples examined (Table 1) there was intense
staining of the nucleus, with no evidence of membrane stain-
ing. Autoantibodies stained nuclei of both mouse and hu-
man cells. For comparison, keratinocytes were stained with
an antibody to desmogleins, the autoantigens of pemphigus
vulgaris and pemphigus foliaceus; as illustrated in Fig. 1 B the
staining pattern was quite distinct from that observed with
autoantibodies from the IFN-g transgenic mice.
Antinuclear Antibodies in IFN-g Transgenic Mice Are Specific
for dsDNA and Histones. To identify proteins recognized
by the autoantibodies from IFN-g transgenic mice, extracts
of cultured mouse and human keratinocytes were resolved on
SDS-PAGE and subjected to immunoblotting (Table 1 and
data not shown). 10 of the 12 serum samples recognized a
single band with an apparent molecular mass of z100 kD.
However, serum from two nontransgenic BALB/c control
mice also recognized the band, indicating that it was not
specific to the transgenic mice. As predicted from the im-
munofluorescence staining shown in Fig. 1, the 100-kD
band was not recognized by a pandesmoglein antibody (data
not shown). Furthermore, the mobility is distinct from that
of the bullous pemphigoid antigens (21).
Next, we tested the serum samples for antibodies to ENA
using counter-current immunoelectrophoresis. Increased lev-
els of autoantibodies against the ENA screened (Sm,
U1RNP, SS-A [Ro], SS-B [La], Jo1, and Scl-70) were de-
tected in one animal only (no. 16 in Table 1). On further
characterization this mouse was found to be positive for
anti-Sm autoantibodies.
To examine whether antibodies to dsDNA were present,
we screened serum for reactivity to the kineoplast of the
flagellate organism C. luciliae. Indirect immunofluorescence
testing of serum on C. luciliae has been used as a specific test
for the presence of anti-dsDNA autoantibodies (22). Serum
samples from 21 transgenic mice and 12 negative littermate
controls were tested. 18 samples from transgenic animals
produced definite staining of the kinetoplast (see Fig. 2 A
and Table 1). All littermate controls were negative on this
test (Table 2).
We used ELISA assays to quantitate the levels of anti-
dsDNA autoantibodies and to determine whether antihis-
tone antibodies were also present. Sera from male (mice
Nos. 1–9 and 19; mean age, 7.4 mo; Table 1) and female
transgenic mice (mice Nos. 10–16; mean age, 8.6 mo; Ta-
ble 1) and negative control littermates (mice C1–C6 for
anti-dsDNA and mice C1–C4, C9, and C10 for antihis-
tone, Table 2), were measured and are shown in Fig. 2, B
and C and Table 3. Compared to littermate controls (mean
OD, 0.038) both male (mean OD, 0.081; P ,0.01) and fe-
male (mean OD, 0.232; P ,0.003) transgenic mice
showed evidence of anti-dsDNA antibody production. Lev-
els were significantly higher in females than males (P
,0.007). All four MRL/lpr mice, included as positive con-
trols, produced higher levels of anti-dsDNA antibody than
the transgenic females (mean OD, 0.848 vs. 0.232, respec-
tively, Fig. 2 B). Female transgenic mice tested produced
antihistone antibodies at levels comparable to MRL/lpr
controls (mean OD, 0.313 and 0.478, respectively, Fig. 2
C). Antihistone antibody levels in serum from male trans-
genic mice did not differ significantly from negative litter-
mate controls (mean OD, 0.011 and 0.013, respectively, Fig.
Figure 2. Screening serum for anti-dsDNA and antihistone autoantibodies. (A) C. luciliae assay. Staining with serum from a transgenic mouse results in
fluorescence of the kinetoplast (arrow) of each organism. A series of 1-mm optical sections through the specimens was obtained with a confocal micro-
scope and a composite image (Z series) was constructed. Scale bar: 10 mm. (B) Anti-dsDNA and (C) antihistone autoantibody levels in transgenic mouse
serum. Sera from 17 transgenic mice and 6 negative littermate controls were tested individually against dsDNA at 1:250 and histones at 1:1,000 dilution.
The OD value for each sample represents the mean of three measurements. LC, Littermate controls; TM, transgenic males; TF, transgenic females. Four
MRL/lpr mice known to produce high levels of antinuclear antibodies are included as positive controls. A serum sample known to be positive for anti-
ssDNA showed no significant binding in the dsDNA ELISA (OD 0.00 6 0.05). All sera were tested on uncoated ELISA plate plastic. Nonspecific bind-
ing to plastic was low (OD on uncoated wells ranged from 0 to 5% of values on antigen-coated wells).1456 Lupus Nephritis in IFN-g Transgenic Mice
2 C). Antinuclear autoantibodies were detected in female
animals from all three transgenic founder lines. Interest-
ingly, mice that produced the highest levels of anti-dsDNA
did not necessarily produce high levels of antihistone anti-
bodies and vise versa (Table 3).
IFN-g Transgenic Mice Have Renal Immune Complex Depo-
sition and GN. Anti-dsDNA antibodies are known to de-
posit in the kidneys of 60–70% of SLE patients and to cause
GN (3, 4). We therefore examined the kidneys of the trans-
genic mice for evidence of autoantibody deposition and
organ damage (Fig. 3). Immunohistochemistry of kidneys
showed dense deposits of IgG within the glomeruli in all
female IFN-g transgenic mice examined (n 5 5, Table 1).
As in human lupus-nephritis, both mesangial (Fig. 3 A) and
capillary (Fig. 3 B) patterns of Ig deposition were found.
Five out of eight male mice tested had evidence of Ig de-
posits in the glomeruli (Table 1).
Histological examination of kidney tissue (16 males and
11 females) demonstrated clear evidence of GN in female
mice only. The severity of the lesion varied from mild me-
sangial nephritis (results not shown) to severe diffuse prolif-
erative GN (Fig. 3 C). The former was observed in mice
from two founder lines, 1205C and 1212F, and overall oc-
curred in z25% of female animals examined (Nos. 12, 14,
and 16, Tables 1 and 3). Subendothelial-mesangial deposits
were confirmed by electron microscopy (Fig. 3 E) and the
immunopathology closely corresponded with the findings
in spontaneous murine lupus–like syndromes (23). Interest-
ingly, severe proliferative GN occurred in female trans-
genic mice with high levels of anti-dsDNA (Table 3).
Control littermates had normal kidneys (n 5 10; Fig. 3 D).
Discussion
We have shown that targeting an IFN-g transgene to the
suprabasal epidermal layers via the involucrin promoter re-
sults in production of antihistone and anti-dsDNA autoan-
tibodies and in immune complex deposition in the kidneys.
Autoantibody levels were higher in female mice than males
and kidney damage was only found in females. These ob-
servations, together with our earlier findings that the mice
had inflammatory skin lesions, dermal edema, and spleno-
megaly (12) suggest that our transgenic mice are a useful
model for SLE. Reevaluating the skin phenotype of the trans-
genic mice in the light of this interpretation, the occasional
separation of epidermis from dermis with infiltration of
hemopoietic cells is probably the hydropic degeneration of
basal cells that is characteristic of SLE (24).
The reason for the higher rate of SLE in females remains
unknown. However, the defects in experimental tolerance
which have been described in spontaneous murine lupus
Table 3. Kidney Pathology and Relative Levels of Antinuclear 
Antibodies in Female IFN-g Transgenic Mice
Animal
Anti-
dsDNA Antihistone Kidney pathology
10 0.143 0.019 Mild mesangial GN
11 0.186 0.194 Mild mesangial GN
12 0.148 0.070 Severe diffuse proliferative GN
13 0.160 0.653 Mild mesangial GN
14 0.303 0.101 Severe diffuse proliferative GN
15 0.173 1.094 Mild mesangial GN
16 0.510 0.063 Severe diffuse proliferative GN
Antibody levels are expressed as OD measured at 492 nm. Anti-dsDNA
and antihistone ELISAs were carried out at dilutions of 1:250 and 1:1,000,
respectively.
Figure 3. Glomerular immunopathology in female transgenic mice.
Immunofluorescence staining of kidney tissue showing deposits of IgG in
the mesangium (A) and globally on capillary walls (B). Hematoxylin and
eosin stained glomerulus from a 10-mo-old female transgenic mouse (C)
and a glomerulus from an age- and sex-matched negative littermate con-
trol (D). In C, note diffuse proliferative GN with hypercellularity, nuclear
fragmentation, and reduction in capillary lumens. There were no signifi-
cant tubulointerstitial or vascular lesions. (E) Electron micrograph of kid-
ney tissue from a 4-mo-old female transgenic mouse shows electron-
dense deposits in a subendothelial-mesangial distribution (arrow) and a
narrowed capillary lumen (n). Scale bar (A–D): 60 mm; (E): 1.5 mm.1457 Seery et al.
are critically dependent on sex hormones, with androgens
exerting a protective effect (for review see reference 25). In
IFN-g transgenic mice, the highest levels of both antihis-
tone and anti-dsDNA autoantibodies were detected in fe-
male animals (Fig. 2, B and C). In addition, histological ev-
idence of kidney pathology was only observed in female
transgenic mice. There was no correlation between antihis-
tone levels and GN severity. Furthermore, while the two
female mice with highest levels of anti-dsDNA antibodies
had marked immune complex deposition in the glomeruli
(Table 1) and severe GN (Table 3), the correlation be-
tween anti-dsDNA levels and kidney damage was not ab-
solute (compare mice 11 and 12, Table 3). This phenome-
non is well described in patients with SLE. The extent of
tissue immune complex deposition, and the degree of or-
gan damage, do not depend solely on the serum titer of anti-
dsDNA antibodies but also on several qualitative properties
of the antibodies (26) and possibly on the host’s ability to
process immune complexes (27).
Previous observations in transgenic mice in which IFN-g
is overexpressed in specific tissues have suggested that local
overproduction of IFN-g is involved in the pathogenesis of
organ specific autoimmunity (17, 18). In contrast, our trans-
genic mice did not produce autoantibodies characteristic of
cutaneous autoimmune disease. Autoantibodies in our mice
reacted with multiple cell types on tissue sections and did
not recognize membrane proteins, including the autoanti-
gens of pemphigus vulgaris or bullous pemphigoid, the two
major autoimmune skin disorders; instead, they recognized
nuclear antigens. In the light of the earlier transgenic stud-
ies, the lack of organ-specific autoimmunity in our trans-
genic system may appear surprising. However, previous stud-
ies have strongly implied that the consequences of IFN-g
overexpression may vary with tissue type. Transgenic expres-
sion of IFN-g in beta-cells results in a cell-mediated immune
destruction of pancreatic islets (17), whereas overexpression
in the neuromuscular junction elicits a humoral response
with no evidence of cell-mediated damage (18). It has been
argued that the response of APCs to cytokines may differ in
different tissue types, leading to different patterns of T cell
activation (28). Certainly, there is evidence that the skin
immune system has distinctive properties, both in terms of
its APC and keratinocyte functions (29) and these may ex-
plain the difference in response to IFN-g overexpression in
the skin compared to other transgenic model systems.
With the exception of one animal, increased levels of
anti-dsDNA antibodies were not accompanied by produc-
tion of autoantibodies against the ENA tested. Interestingly,
the single mouse with anti-ENA antibodies was found to
be positive for anti-Sm autoantibodies, a serological finding
considered highly specific for SLE (30). However, the con-
sistent generation of high levels of antihistone and anti-
dsDNA antibodies in our transgenic mice in the absence of
significant autoreactivity to ENA supports the concept that
different pathogenic mechanisms underlie the generation of
the two types of autoantibody (31).
There is strong evidence that presentation of nuclear an-
tigens to CD4-positive T cells is involved in the produc-
tion of pathogenic anti-dsDNA autoantibodies (1) and De-
sai-Mehta et al. have isolated and characterized a subset of
autoimmune T helper cells from patients with SLE (32) which
strongly induce anti-dsDNA antibody production. Immu-
nological abnormalities in the skin of IFN-g transgenic mice
suggest two possible mechanisms of autoantigen presentation
to T cells. IFN-g transgenic mice demonstrate a marked al-
teration in Langerhans cell distribution, consistent with mi-
gration from the epidermis to the dermis and the draining
lymph nodes (12). These “professional” APCs could inter-
act with autoreactive T cells in either site. However, trans-
genic mice also markedly upregulate keratinocyte MHC
class II and intracellular adhesion molecule–1 expression
and there is evidence of low level CD4-positive lympho-
cyte migration into the epidermis in some animals (12).
Therefore, it is possible that keratinocytes play the key role
in autoantigen presentation. It is known that IFN-g can in-
duce translocation of nuclear antigens from the nucleus to
the cytoplasm in epithelial cells and that keratinocytes may
act as APCs under certain conditions (33, 34). Kerati-
nocytes in IFN-g transgenic mice do not express the co-
stimulatory molecule B7 (12). However, antigen presenta-
tion to T cells in the absence of costimulatory molecules
could trigger an aberrant autoreactive immune response
and, indeed, defective antigen presentation is a feature of
SLE (35).
Skin lesions are one of the classical clinical manifestations
of SLE. Our findings are consistent with a central role for
IFN-g and the skin immune system in the pathogenesis of
the systemic complications of the disease. Elucidation of the
precise mechanisms involved in the generation of antinuclear
autoantibodies by the skin immune system in these animals
may give valuable insights into the pathogenesis of SLE.
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